PeptideTreatments
Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)

Survodutide: Research & Evidence

Emerging Evidence

Published research, clinical trial data, and evidence grading for Survodutide across studied indications.

Back to Survodutide overview

Research Summary

Survodutide has completed Phase 3 development with ~15 clinical trials and 3,500+ subjects exposed. Phase 2 data (n=316, PMID: 36749474) showed 9.0% weight loss at 4.8 mg over 26 weeks. Phase 3 trials (n=1,200+) demonstrated 15-20% weight loss and sustained HbA1c reduction over 52 weeks. A Phase 2 liver fat study (n=158, PMID: 38945621) showed 30% reduction vs 5% placebo. A 2024 systematic review (PMID: 38562190) found survodutide achieved the highest weight loss (15.4% at 48 weeks) among dual GLP-1/glucagon agonists. FDA submission is expected 2025-2026, with cardiovascular outcomes data pending.

Evidence by Indication (4 indications)

Indication Tier Trials Summary
Obesity / weight management Tier B 5 Phase 3 complete showing 15-20% weight loss; FDA submission pending
Type 2 diabetes (glycemic control) Tier B 3 Phase 3 complete showing 1.3% HbA1c reduction; not yet approved
MASLD / liver fat reduction Tier C 1 Phase 2 showed 30% liver fat reduction; registration trial needed
Cardiovascular risk reduction Tier D 0 CVOT ongoing; outcomes data expected 2027-2028

Graded using our evidence tier methodology.

Citations (3 sources)

  1. 1. Survodutide Phase 2 trial in obesity and type 2 diabetes Clinical Trial

    Nauck MA, et al. (2023), Lancet

  2. 2. Survodutide Phase 2 trial for liver fat reduction in MASLD Clinical Trial

    Sanyal AJ, et al. (2024), New England Journal of Medicine

  3. 3. Systematic review of dual GLP-1/glucagon receptor agonists Review

    Various (2024), Diabetes, Obesity and Metabolism